What did @harleymeds.com actually say?
The creator, representing a clinic called Harley Meds, said most new patients start testosterone replacement therapy between "100 and 150 milligrams" per week (implied, though frequency was never stated). They described a follow-up blood test at three months to assess levels and adjust dosing. They also quoted a flat monthly price of $169 for the full TRT program.
This is a direct-to-consumer pitch. The video ends with a call to action: comment "TRT" in the comments and they will send you program information. That context matters when evaluating the framing of every claim made before it.
absent: no mention of injection frequency, ester type (cypionate vs. enanthate vs. other), administration route, or what "fully optimized" actually means in clinical terms. That is a significant omission for a video about dosing.
Does the science back this up?
The 100-150mg range is broadly consistent with standard clinical practice for hypogonadism treatment, but the framing skips enough detail to be potentially misleading. Whether that dose is appropriate depends entirely on the individual, the ester, and the injection schedule.
The Endocrine Society's 2018 clinical practice guidelines recommend testosterone cypionate or enanthate starting doses of 75-100mg per week, or 150-200mg every two weeks, for adult males with confirmed hypogonadism. The three-month follow-up bloodwork is also guideline-consistent. Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) confirmed that serum testosterone levels should be assessed at three and six months after initiation to guide dose adjustments.
A 2023 review by Corona et al. in the Journal of Sexual Medicine reinforced that individualized titration, not a fixed starting dose, is the standard of care. The 100-150mg range the creator describes is a reasonable population-level starting window, but presenting it as a simple answer to "what is a good starting dosage" strips away necessary clinical nuance.
What did they get wrong (or right)?
They got the dose range roughly right. The three-month bloodwork check is also legitimate clinical practice. Credit where it is due.
What they got wrong is the framing. The phrase "fully optimized" is not a clinical benchmark. There is no peer-reviewed definition of testosterone optimization for otherwise healthy men without diagnosed hypogonadism. The Endocrine Society explicitly does not recommend TRT for men with age-related testosterone decline in the absence of clinical hypogonadism symptoms and confirmed low levels on at least two morning draws.
The creator never mentioned injection frequency, which fundamentally changes how a dose behaves. 150mg once a week produces different peak and trough serum levels than 150mg every two weeks. Morgentaler et al. (2016, Mayo Clinic Proceedings) documented that dosing intervals affect not just efficacy but also hematocrit risk and cardiovascular parameters. Presenting a milligram number without a schedule is incomplete to the point of being misleading.
The sales call-to-action at the end also warrants scrutiny. A video that opens with a clinical question and closes with "comment TRT and I'll send you the info" is marketing dressed as education.
What should you actually know?
If you are considering TRT, the starting dose is almost the least important variable. Here is what actually matters before you agree to anything.
- Confirmed diagnosis matters first. TRT is FDA-approved for hypogonadism, which requires two morning testosterone draws below 300 ng/dL combined with clinical symptoms. Using TRT without a confirmed diagnosis is off-label use with real risks.
- Injection frequency shapes your experience as much as dose. Weekly injections produce steadier levels than biweekly injections. Subcutaneous vs. intramuscular delivery also affects absorption rates.
- Three months for a first follow-up is guideline-consistent, but some clinicians check at six weeks post-initiation. Pellitteri et al. (2021, Urology) noted that earlier checks can catch hematocrit elevation before it becomes clinically significant.
- The cardiovascular question is not settled. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found TRT did not increase major cardiovascular events in men with hypogonadism and elevated cardiovascular risk, but this data applies to diagnosed patients, not anyone pursuing hormone optimization.
- A flat $169 monthly price is not inherently suspicious, but you should know what is and is not included: labs, physician oversight, follow-up visits, and what happens if you need a dose adjustment or develop side effects.